Clinical trial
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
Abstract
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor (SSRI) escitalopram for major depressive disorder (MDD).
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
This study's objects
Directly linked records, matched by DOI, trial reference, or registry, not just topic.
Publications from this trial
ArticlePsilocybin
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
ArticlePsilocybin
Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
ArticlePsilocybin
A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.
ArticlePsilocybin
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.
ArticlePsilocybin
Psychedelics and the 'inner healer': Myth or mechanism?
ArticlePsilocybin
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.
Related research
ArticlePsilocybin
Association of Psilocybin Use in Adolescents with Major Depressive Episode
ArticlePsilocybin
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
ArticlePsilocybin